Symbols

TXG

10x Genomics·NASDAQ

--(--)

TXG fundamentals

TXG Q4 2025 Earnings

10x Genomics (TXG) released its earnings on Feb 12, 2026: revenue was 166.03M (YoY +0.61%), beat estimates; EPS was -0.13 (YoY +67.50%), beat estimates.

Revenue / YoY

166.03M

+0.61%

EPS / YoY

-0.13

+67.50%

Report date

Feb 12, 2026

TXG Earnings Call Summary for Q4,2025

Revenue Resilience: Q4 2025 revenue of $166 million exceeded guidance, with full-year growth despite macro challenges.
Product Momentum: Flex Apex adoption drove single-cell consumables growth, while Xenium solidified spatial leadership with 14% revenue growth.
Strategic Expansion: Clinical collaborations (e.g., Dana-Farber) and AI-driven projects (e.g., Chan Zuckerberg Initiative) position for future growth.
Financial Strength: $523 million cash balance supports R&D and strategic initiatives, with 2026 guidance reflecting cautious but stable outlook.
Key Risks: Capital spending constraints limit instrument sales, and pricing pressures in single-cell offset volume gains.

Earnings

EPS

Revenue

Revenue & Expenses

TXG has released its 2025 Q4 earnings report, with revenue of 166.03M, reflecting a YoY change of 0.61%, and net profit of -16.25M, showing a YoY change of 66.85%. The Sankey diagram below clearly presents TXG's revenue sources and cost distribution.

Key Indicators

10x Genomics (TXG) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

10x Genomics (TXG)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

10x Genomics (TXG)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

10x Genomics (TXG)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown